S&P 500   3,854.21 (+0.06%)
DOW   31,195.02 (+0.02%)
QQQ   325.96 (+0.68%)
AAPL   136.13 (+3.11%)
MSFT   225.99 (+0.74%)
FB   272.33 (+1.81%)
GOOGL   1,888.50 (+0.45%)
AMZN   3,318.00 (+1.67%)
TSLA   847.59 (-0.34%)
NVDA   544.98 (+1.94%)
BABA   259.44 (-2.28%)
CGC   33.85 (+0.65%)
GE   11.11 (-2.46%)
MU   83.53 (+0.04%)
AMD   90.82 (+2.33%)
NIO   57.92 (+0.36%)
T   28.91 (-0.17%)
F   11.63 (+7.09%)
ACB   11.11 (-3.73%)
BA   207.08 (-2.07%)
DIS   172.59 (-0.60%)
NFLX   575.07 (-1.92%)
GILD   67.05 (-1.38%)
S&P 500   3,854.21 (+0.06%)
DOW   31,195.02 (+0.02%)
QQQ   325.96 (+0.68%)
AAPL   136.13 (+3.11%)
MSFT   225.99 (+0.74%)
FB   272.33 (+1.81%)
GOOGL   1,888.50 (+0.45%)
AMZN   3,318.00 (+1.67%)
TSLA   847.59 (-0.34%)
NVDA   544.98 (+1.94%)
BABA   259.44 (-2.28%)
CGC   33.85 (+0.65%)
GE   11.11 (-2.46%)
MU   83.53 (+0.04%)
AMD   90.82 (+2.33%)
NIO   57.92 (+0.36%)
T   28.91 (-0.17%)
F   11.63 (+7.09%)
ACB   11.11 (-3.73%)
BA   207.08 (-2.07%)
DIS   172.59 (-0.60%)
NFLX   575.07 (-1.92%)
GILD   67.05 (-1.38%)
S&P 500   3,854.21 (+0.06%)
DOW   31,195.02 (+0.02%)
QQQ   325.96 (+0.68%)
AAPL   136.13 (+3.11%)
MSFT   225.99 (+0.74%)
FB   272.33 (+1.81%)
GOOGL   1,888.50 (+0.45%)
AMZN   3,318.00 (+1.67%)
TSLA   847.59 (-0.34%)
NVDA   544.98 (+1.94%)
BABA   259.44 (-2.28%)
CGC   33.85 (+0.65%)
GE   11.11 (-2.46%)
MU   83.53 (+0.04%)
AMD   90.82 (+2.33%)
NIO   57.92 (+0.36%)
T   28.91 (-0.17%)
F   11.63 (+7.09%)
ACB   11.11 (-3.73%)
BA   207.08 (-2.07%)
DIS   172.59 (-0.60%)
NFLX   575.07 (-1.92%)
GILD   67.05 (-1.38%)
S&P 500   3,854.21 (+0.06%)
DOW   31,195.02 (+0.02%)
QQQ   325.96 (+0.68%)
AAPL   136.13 (+3.11%)
MSFT   225.99 (+0.74%)
FB   272.33 (+1.81%)
GOOGL   1,888.50 (+0.45%)
AMZN   3,318.00 (+1.67%)
TSLA   847.59 (-0.34%)
NVDA   544.98 (+1.94%)
BABA   259.44 (-2.28%)
CGC   33.85 (+0.65%)
GE   11.11 (-2.46%)
MU   83.53 (+0.04%)
AMD   90.82 (+2.33%)
NIO   57.92 (+0.36%)
T   28.91 (-0.17%)
F   11.63 (+7.09%)
ACB   11.11 (-3.73%)
BA   207.08 (-2.07%)
DIS   172.59 (-0.60%)
NFLX   575.07 (-1.92%)
GILD   67.05 (-1.38%)
Log in
NYSE:EW

Edwards Lifesciences Competitors

$87.62
-0.48 (-0.54 %)
(As of 01/21/2021 01:33 PM ET)
Add
Compare
Today's Range
$86.65
Now: $87.62
$88.76
50-Day Range
$83.57
MA: $87.59
$91.23
52-Week Range
$51.51
Now: $87.62
$92.08
Volume30,029 shs
Average Volume2.54 million shs
Market Capitalization$54.61 billion
P/E Ratio70.10
Dividend YieldN/A
Beta0.97

Competitors

Edwards Lifesciences (NYSE:EW) Vs. ABT, MDT, ISRG, SYK, BDX, and BSX

Should you be buying EW stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Edwards Lifesciences, including Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), and Boston Scientific (BSX).

Abbott Laboratories (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Risk & Volatility

Abbott Laboratories has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Earnings and Valuation

This table compares Abbott Laboratories and Edwards Lifesciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.24$3.69 billion$3.2434.66
Edwards Lifesciences$4.35 billion12.51$1.05 billion$1.8646.94

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Edwards Lifesciences18.18%29.00%18.10%

Institutional & Insider Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Abbott Laboratories and Edwards Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121302.75
Edwards Lifesciences271202.48

Abbott Laboratories currently has a consensus price target of $115.6875, indicating a potential upside of 3.05%. Edwards Lifesciences has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Given Edwards Lifesciences' higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Abbott Laboratories.

Summary

Edwards Lifesciences beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Institutional & Insider Ownership

79.2% of Medtronic shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Medtronic and Edwards Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic032012.92
Edwards Lifesciences271202.48

Medtronic currently has a consensus price target of $122.2963, indicating a potential upside of 4.14%. Edwards Lifesciences has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than Edwards Lifesciences.

Earnings and Valuation

This table compares Medtronic and Edwards Lifesciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.49$4.79 billion$4.5925.67
Edwards Lifesciences$4.35 billion12.51$1.05 billion$1.8646.94

Medtronic has higher revenue and earnings than Edwards Lifesciences. Medtronic is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic12.69%9.71%5.30%
Edwards Lifesciences18.18%29.00%18.10%

Risk & Volatility

Medtronic has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Medtronic on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Edwards Lifesciences and Intuitive Surgical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences271202.48
Intuitive Surgical381002.33

Edwards Lifesciences presently has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Intuitive Surgical has a consensus price target of $719.6471, indicating a potential downside of 8.87%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Edwards Lifesciences is more favorable than Intuitive Surgical.

Earnings & Valuation

This table compares Edwards Lifesciences and Intuitive Surgical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.51$1.05 billion$1.8646.94
Intuitive Surgical$4.48 billion20.75$1.38 billion$9.9579.47

Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Intuitive Surgical24.45%12.08%10.44%

Volatility & Risk

Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Summary

Intuitive Surgical beats Edwards Lifesciences on 9 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 71.5% of Stryker shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 6.8% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Edwards Lifesciences and Stryker, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences271202.48
Stryker271412.58

Edwards Lifesciences presently has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Stryker has a consensus price target of $227.4783, indicating a potential downside of 5.78%. Given Edwards Lifesciences' higher possible upside, equities analysts clearly believe Edwards Lifesciences is more favorable than Stryker.

Earnings & Valuation

This table compares Edwards Lifesciences and Stryker's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.51$1.05 billion$1.8646.94
Stryker$14.88 billion6.14$2.08 billion$8.2629.42

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Stryker12.35%20.94%8.77%

Volatility & Risk

Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Stryker on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 83.2% of Becton, Dickinson and shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Edwards Lifesciences and Becton, Dickinson and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences271202.48
Becton, Dickinson and07702.50

Edwards Lifesciences presently has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Becton, Dickinson and has a consensus price target of $281.0769, indicating a potential upside of 7.40%. Given Becton, Dickinson and's stronger consensus rating and higher possible upside, analysts clearly believe Becton, Dickinson and is more favorable than Edwards Lifesciences.

Earnings & Valuation

This table compares Edwards Lifesciences and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.51$1.05 billion$1.8646.94
Becton, Dickinson and$17.12 billion4.45$874 million$10.2025.69

Edwards Lifesciences has higher earnings, but lower revenue than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Becton, Dickinson and5.11%13.30%5.60%

Volatility & Risk

Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Becton, Dickinson and on 8 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 90.7% of Boston Scientific shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.7% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Edwards Lifesciences and Boston Scientific, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences271202.48
Boston Scientific031722.95

Edwards Lifesciences presently has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Boston Scientific has a consensus price target of $43.0870, indicating a potential upside of 15.36%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than Edwards Lifesciences.

Earnings & Valuation

This table compares Edwards Lifesciences and Boston Scientific's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.51$1.05 billion$1.8646.94
Boston Scientific$10.74 billion4.98$4.70 billion$1.5823.65

Boston Scientific has higher revenue and earnings than Edwards Lifesciences. Boston Scientific is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Boston Scientific36.59%11.77%5.57%

Volatility & Risk

Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Summary

Boston Scientific beats Edwards Lifesciences on 8 of the 15 factors compared between the two stocks.

Ad Emerging Markets Consulting
Wish you would have bought Draft Kings?
Here's an undiscovered gaming play with massive potential.

Edwards Lifesciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$112.31-0.5%$200.08 billion$31.90 billion59.42Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.7$117.83-1.2%$160.57 billion$28.91 billion44.97Decrease in Short Interest
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.5$790.70-1.0%$93.88 billion$4.48 billion90.06Analyst Revision
Stryker logo
SYK
Stryker
2.0$243.04-0.9%$92.15 billion$14.88 billion52.72Upcoming Earnings
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$262.02-0.5%$76.58 billion$17.12 billion95.98
Boston Scientific logo
BSX
Boston Scientific
2.2$37.37-1.9%$52.49 billion$10.74 billion14.32
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$493.45-0.3%$42.23 billion$2.41 billion85.97Decrease in Short Interest
Baxter International logo
BAX
Baxter International
2.3$79.52-0.0%$40.62 billion$11.36 billion45.18
DexCom logo
DXCM
DexCom
1.9$365.81-0.5%$34.97 billion$1.48 billion151.16Increase in Short Interest
ResMed logo
RMD
ResMed
1.4$216.04-0.9%$31.59 billion$2.96 billion46.36Upcoming Earnings
Insider Selling
Hologic logo
HOLX
Hologic
1.9$75.23-2.6%$19.85 billion$3.78 billion17.91Upcoming Earnings
Insulet logo
PODD
Insulet
1.3$292.01-0.4%$19.32 billion$738.20 million663.67Gap Down
Teleflex logo
TFX
Teleflex
2.0$391.27-0.5%$18.31 billion$2.60 billion50.36
STERIS logo
STE
STERIS
2.1$188.56-0.5%$16.17 billion$3.03 billion38.25Analyst Report
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.66-0.1%$16.07 billion$3.17 billion59.95Upcoming Earnings
Abiomed logo
ABMD
Abiomed
1.5$348.91-0.3%$15.72 billion$840.88 million76.68Upcoming Earnings
Masimo logo
MASI
Masimo
1.4$260.23-1.3%$14.51 billion$937.84 million67.59Decrease in Short Interest
Hill-Rom logo
HRC
Hill-Rom
2.0$99.44-2.9%$6.83 billion$2.88 billion29.95
Globus Medical logo
GMED
Globus Medical
1.4$65.61-0.4%$6.45 billion$785.37 million71.32
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.65-0.7%$5.91 billion$1.52 billion103.96Analyst Report
NuVasive logo
NUVA
NuVasive
1.3$57.53-0.1%$2.95 billion$1.17 billion-261.50
Integer logo
ITGR
Integer
2.3$78.43-0.9%$2.60 billion$1.26 billion35.65
AtriCure logo
ATRC
AtriCure
1.3$57.00-0.4%$2.58 billion$230.81 million-49.57Analyst Report
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$46.12-0.5%$1.84 billion$236.54 million-69.88
Alphatec logo
ATEC
Alphatec
0.8$14.66-1.4%$1.17 billion$113.43 million-13.33
CryoLife logo
CRY
CryoLife
1.7$24.78-0.6%$968.71 million$276.22 million-65.21
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$43.31-2.2%$856.11 million$459.95 million36.09Decrease in Short Interest
AngioDynamics logo
ANGO
AngioDynamics
1.6$18.58-1.0%$712.21 million$264.16 million-4.16Gap Up
Surmodics logo
SRDX
Surmodics
1.5$44.27-1.1%$612.27 million$94.86 million553.38
Accuray logo
ARAY
Accuray
2.1$5.09-5.7%$491.05 million$382.93 million36.36Upcoming Earnings
Invacare logo
IVC
Invacare
1.6$10.08-3.2%$357.95 million$927.96 million-8.20Gap Up
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.38-6.9%$119.77 million$61.30 million-3.20Analyst Upgrade
News Coverage
Gap Down
This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.